Mountain Valley MD Holdings (MVMD.CN) stock remarkably climbed despite the low price. The one-month chart illustrates that the stock started from C$0.4700 on June 22. However, day by day the price gradually declined by fluctuating from C$0.4700 to C$0.2450 on July 13. Despite this, the stock dramatically rose to C$0.4900 on July 19. Finally, it slightly fell and finished at C$0.4500 on July 20. Mountain Valley MD Holdings nominated Gokul Kannan and Mark Gelnaw as consultants to the Company. Gokul Kannan has over 7 years of experience in the area of research at UC Berkeley, Johns Hopkins, and Gilead and collaborated with doctors such as Sanjay Kumar, Richard Saykally, Takanori Takebe, and Sapna Kudchadkar. Furthermore, he is a partner at Zephyr Venture Partners and a rising star in bioengineering and chemical engineering research.
Mark Gelnaw has over 35 years of experience in financial management, business management, and corporate strategy. Additionally, he was the CEO and CFO of cancer research organization Cynvec LLC. Mountain Valley MD Holdings also confirmed that it processes its stock listing application for trading on the TSX Venture Exchange. The company also announced that stock grant options of approximately 3,725,000 were given to certain directors, officials, staff, consultants, and advisers as bonus stock options at a price of $0.27 per share.